Abstract:OBJECTIVE To investigate the therapeutic effect and safety of linezolid and vancomycin in the treatment of the senile patients with ventilator-associated pneumonia induced by methicillin-resistant Staphylococcus aureus(MRSA)and evaluate the clinical efficacy and safety of linezolid.METHODS The therapeutic effect,bacterial clearance,treatment course and incidence of adverse reactions such as renal function abnormality,leucopenia,neutropenia,thrombocytopenia and renal dysfunction were compared between the vancomycin group(28cases treated with vancomycin)and the linezolid group(23cases treated with linezolid).RESULTS Totally 89strains of pathogenic bacteria were isolated from the sputum specimens obtained from 51patients,including 51strains of MRSA.The drug susceptibility testing showed that the linezolid and vancomycin had the extremely high antibacterial activity against the 51strains of MRSA,with the drug susceptibility rate reaching to 100.0%.There were 17cases cured and 3cases improved in the linezolid group with the total effective rate of 86.96%;there were 14cases cured and 3cases improved in the vancomycin group with the total effective rate of 60.71%,the difference between the two groups was significant(P<0.05).After the treatment,the clearance rate of MRSA was 82.61%in the linezolid group,57.14%in the vancomycin group,the difference was significant(P<0.05);the treatment course was(13.57±3.12)days in the linezolid group,(16.92±5.47)days in the vancomycin group,the difference was significant(P<0.05);there were 3(13.04%)cases of patients with the reduction in platelet counts more than 25%in the linezolid group and 1case(3.57%)in the vancomycin group;the difference in the incidence of leucopenia or neutropenia between the two groups was not significant;there were 2cases with acute renal dysfunction in the vancomycin group and no case in the linezolid group.CONCLUSION The clinical efficacy of linezolid is superior to vancomycin in the treatment of senile patients with VAP caused by MRSA,but it is necessary to be aware of the risk of thrombocytopenia.

Evaluation of Norvancomycin in Treatment of MRS Infections

The effect of norvancomycin on the infection of MRS and the evaluation of the bacteriological investigation

Population Pharmacokinetic and Pharmacodynamic Modeling of Norvancomycin

Norvancomycin for the treatment of central nervous system MRSA infections: A randomized controlled trial

Multicenter Randomized Controlled Clinical Trial on Teicoplanin Versus Vancomycin

[The Adverse Reactions of Parenteral Norvancomycin in 1031 Patients].

Clinical Pharmacokinetics and Therapeutic Drug Monitoring of Norvancomycin

The study on adverse reactions induced by vancomycin or norvancomycin

Study on the in vitro antibacterial activities of the antibacterial drugs against methicillin resistant coagulase-negative staphylococci

Pharmacokinetics of Norvancomycin of SICU Patients

Clinical research on efficacy of linezolid and vancomycin in treatment of senile patients with ventilator-associated pneumonia induced by MRSA

Vancomycin Serum Trough Concentration Vs. Clinical Outcome in Patients with Gram-Positive Infection: a Retrospective Analysis.

Determination of Norvancomycin Epidemiological Cut-off Values (ecoffs) for Staphylococcus Aureus, Staphylococcus Epidermidis, Staphylococcus Haemolyticus and Staphylococcus Hominis

[Recent findings based on the results of the post-marketing surveillance of vancomycin hydrochloride for intravenous infusion]

Teicoplanin and Vancomycin Treatment in Patients with Lung Infection of MRSA:A Clinical Evaluation

Effects of augmented renal clearance on the outcome of vancomycin /norvancomycin

In vivo activity of antibiotic 89-07 combined with flomoxef in the experimental therapy of mouse septicemia infected by mec A gene positive MRSA

Effects and Safety of Linezolid vs.Vancomycin for the Treatment of Patients with MRSA: Meta Analysis of Randomized Controlled Trials

Retrospective Analysis of the Use of Vancomycin Therapy in the Treatment of Infection Diseases

Effectiveness and safety of enteral vancomycin to control endemicity of methicillin-resistant Staphylococcus aureus in a medical/surgical intensive care unit

Efficacy and safety of vancomycin compared with those of alternative treatments for methicillin‐resistant Staphylococcus aureus infections: An umbrella review